Author: Customer Service

Dassault Systèmes’ CEO Pascal Daloz becomes also Chairman of the Board of Directors of Dassault Systèmes

Written by Customer Service on February 21, 2026. Posted in Public Companies.

Press ReleaseVELIZY-VILLACOUBLAY, France — February 21, 2026 Dassault Systèmes’ CEO Pascal Daloz becomes also Chairman of the Board of Directors of Dassault SystèmesBernard Charlès announces stepping down from his Executive Chairman and Member of the Board positions, for personal reasons Bernard Charlès intends to put his 43 years of industry experience, and his vision to transform, with AI, industrial creation and production processes, at the service of the Generative Economy Pascal Daloz is appointed Chairman and Chief Executive Officer by Dassault Systèmes’ Board, pursuing the 3D UNIV+RSES ambition to position Dassault Systèmes as leader in Industrial AIDassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) announces that Bernard Charlès has informed the Board of Directors, today and with immediate effect, that he is stepping...

AnorTech Grants Stock Options

Written by Customer Service on February 21, 2026. Posted in Public Companies.

VANCOUVER, British Columbia, Feb. 21, 2026 (GLOBE NEWSWIRE) — ANORTECH INC. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTCQB “ANORF”) has granted incentive stock options under the Company’s stock option plan to directors, employees and consultants to purchase a total of 5,150,000 shares at a price of $0.10 per share. The options vest over 18 months and have a term of five years, subject to the policies of the TSX Venture Exchange. ON BEHALF OF THE BOARD OF DIRECTORS “Jim Cambon” President and Director For further information:Ph: 778-373-2164www.anortechinc.com Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Written by Customer Service on February 21, 2026. Posted in Public Companies.

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 202622 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod’s potential in inflammatory bowel disease Anti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn’s disease A pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials demonstrates a favorable safety profile with rates of serious treatment emergent adverse events and study discontinuation similar to placebo Symptomatic response of obefazimod was observed as early as week...

Rakovina Therapeutics Announces Upsized Financing Up to $2.0 Million

Written by Customer Service on February 21, 2026. Posted in Public Companies.

Proposed $1.0 Million Convertible Debenture and Warrant Financing and Concurrent Common Share Private Placement Up to $1.0 Million Intended to Support Near-Term Operations VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that its previously announced financing has been upsized up to approximately $2 million. On January 27th, the Company announced that it has reached an agreement in principle with an existing investor to invest an additional $1.0 million in the Company by way of a non-brokered private placement (the “Debenture Private Placement”) of an unsecured convertible debenture and two million common share purchase...

VERSES Announces Filing of Quarterly Report on Form 10-Q for the Three and Nine-Months Ended December 31, 2025

Written by Customer Service on February 21, 2026. Posted in Public Companies.

VANCOUVER, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) (“VERSES” or the “Company”), a cognitive computing company pioneering next-generation agentic software systems today announced that it has filed its Quarterly Report on Form 10-Q (“Quarterly Report”) for the three months and nine months ended December 31, 2025, with the U.S. Securities and Exchange Commission (“SEC”). “We are pleased to report our results for the three months and nine months ending December 31, 2025 in our Quarterly Report on Form 10-Q and will review those results on our earnings call scheduled for Tuesday February 24th at 1:00 PM Eastern time.” said James Christodoulou, CFO of VERSES. In conjunction with this release, Verses will host a conference call, which will be simultaneously...

K2 Capital Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Rights, Commencing on February 25, 2026

Written by Customer Service on February 20, 2026. Posted in Public Companies.

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) — K2 Capital Acquisition Corp. (the “Company”) today announced that, commencing on February 25, 2026, holders of the 13,800,000 units (the “Units”) sold in the Company’s initial public offering (the “Offering”), including Units sold upon full exercise of the underwriters’ over-allotment option, may elect to separately trade the Class A ordinary shares and rights included in the Units. Any Units not separated will continue to trade on the NASDAQ Global Market (“NASDAQ”) under the symbol “KTWOU.” Any underlying Class A ordinary shares and rights that are separated will trade on the NASDAQ under the symbols “KTWO” and “KTWOR,” respectively. Holders of Units will need to have their brokers contact the Company’s transfer agent, VStock Transfer, in order to separate the holders’...

Helios Fairfax Partners Corporation Closes Amendment to Credit Facility

Written by Customer Service on February 20, 2026. Posted in Public Companies.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Feb. 20, 2026 (GLOBE NEWSWIRE) — Helios Fairfax Partners Corporation (“Helios Fairfax”) (TSX: HFPC.U) announces that it has closed an amendment and restatement of its existing credit facility with FirstRand Bank Limited (acting through its Rand Merchant Bank division) (the “Amended Credit Facility”). The key modifications to the Amended Credit Facility include the following:Facility Increase: The lenders have increased their commitments on the secured revolving credit facility to US$85 million, with an option for Helios Fairfax to request an additional increase of US$15 million. Purpose: The secured revolving credit facility is to be used for the purpose of (a) making investments in accordance with Helios Fairfax’s investment objectives...

AirBoss to Release 4th Quarter and FY 2025 Earnings on March 4, 2026

Written by Customer Service on February 20, 2026. Posted in Earnings Releases And Operating Results.

NEWMARKET, Ontario, Feb. 20, 2026 (GLOBE NEWSWIRE) — AirBoss of America Corp. (TSX: BOS) (OTCQX:ABSSF) (the “Company” or “AirBoss”) today announced that it will release its fourth quarter and unaudited full year 2025 results after markets close on March 4, 2026. The release will be followed by a conference call to discuss the results on Thursday, March 5, 2026, at 9:00 am ET. The Company will file its audited annual consolidated financial statements and related management’s discussion and analysis for the year ended December 31, 2025 following the conclusion of the audit and in accordance with applicable securities laws. FOURTH QUARTER AND ANNUAL 2025 FINANCIAL RESULTS CONFERENCE CALL DETAILS:DATE: Thursday, March 5, 2026TIME: 9:00 am ETDIAL-IN NUMBER: 1-800-715-9871 or 1-647-932-3411 – ask to join the AirBoss call or...

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

Written by Customer Service on February 20, 2026. Posted in Public Companies.

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds (“PsyLabs“) has exercised its rights under a previously disclosed put option agreement (the “Put Option Agreement“), pursuant to which Psyence BioMed will make an equity investment in PsyLabs at a fair market value determined in accordance with the terms of the Put Option Agreement. The Put Option Agreement was previously disclosed by Psyence BioMed and forms part of the broader strategic and commercial relationship between the two vertically integrated...

Constellation Software Inc. Announces Change to the Date of the Conference Call to Discuss Fourth Quarter Results

Written by Customer Service on February 20, 2026. Posted in Earnings Releases And Operating Results.

TORONTO, Feb. 20, 2026 (GLOBE NEWSWIRE) — Constellation Software Inc. (TSX:CSU) announced on February 17, 2026 that it would be holding its fourth quarter conference call on March 10, 2026 at 8:00 am. Constellation has changed the date of the conference call to March 9, 2026 at 8:30 am. The Company’s quarterly results will be disseminated via press release, and made available on the Company’s website (www.csisoftware.com) and SEDAR+ (www.sedarplus.ca), at 7:00 am EST on Monday, March 9, 2026. Mark Miller, President, Jamal Baksh, Chief Financial Officer, and Bernard Anzarouth, Chief Investment Officer will be available during the March 9, 2026 conference call to answer questions regarding the Company’s results. To access the call, please dial 1-877-879-1183 (North America toll free) or 1-412-902-6703 (International) and using conference...

Author: Customer Service

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals